Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients

Liver Cancer Clinical Trial

Official title:

Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05343832
• Other study ID #: 20210280
• Status: Enrolling by invitation
• Start date: November 29, 2021
• Est. completion date: April 25, 2023

Study information

• Verified date: April 2022
• Source: Genetron Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This trail is a multi-center,prospective observational study aimed to detect early-stage Hepatocellular Carcinoma by a Novel Blood-based DNA Methylation Assay(named Genetron HCC Methylation PCR Kit ). The accuracy of the kit will also be evaluated . The trail will be enroll approximately 4816 participants, including participants with HCC or benign diseases, and high risk factors for liver cancer.

Description:

Diagnostic performance evaluation:

Alpha-fetoprotein (AFP), liver ultrasound (US), dynamic contrast enhanced MRI and the kit examination will be performed on high-risk participants of primary liver cancer.

For subjects with typical imaging findings of hepatocellular carcinoma but an intrahepatic nodule diameter of ≤2 cm, an imaging study will be added to the above.

According to the clinical diagnostic criteria of primary liver cancer, the diagnostic performance of the kit, liver ultrasound examination (US) combined with alpha fetoprotein (AFP) detection will be evaluated, and the sensitivity of the kit, the kit combined with AFP, the kit combined with AFP and US, AFP combined with US screening for primary liver cancer will be compared.

Test performance evaluation:

Plasma samples of patients with and without HCC diagnosed according to the clinical diagnostic criteria of primary HCC will be collected and examined simultaneously by the kit and high-throughput human methylation sequencing (NGS sequencing).

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 4816
• Est. completion date: April 25, 2023
• Est. primary completion date: March 5, 2023
• Gender: All
• Age group: N/A and older

Eligibility

Diagnostic performance evaluation:

Inclusion Criteria:

1. Have high risk factors for liver cancer such as HBV and/or HCV infection, alcoholic liver disease, non-alcoholic steatohepatitis, long-term consumption of food contaminated with aflatoxin, liver cirrhosis caused by various other reasons, and family history of liver cancer Wait;

2. I or my legal representative can read, understand and sign the informed consent;

3. Agree to provide blood samples, be able to receive imaging examinations and have good clinical compliance;

4. The complete clinical basic information includes: the patient's unique traceability number (ID number/outpatient clinic number/medical insurance card number), age, gender, etc.

Exclusion Criteria:

1. pregnant women;

2. Have received an organ transplant;

3. Diagnosed with other tumors;

4. The investigators judged that they were not eligible for inclusion.

Test performance evaluation:

Inclusion Criteria:

1. Confirmed primary hepatocellular carcinoma or confirmed non-HCC;

2. I or my legal representative can read, understand and sign the informed consent;

3. Agree to provide blood samples and have good clinical compliance;

4. The basic clinical information is complete, including: the patient's unique traceability number (ID number/outpatient clinic number/medical insurance card number), age, gender, imaging and/or pathological diagnosis results (for patients with primary liver cancer), imaging examination confirmed non-identical Liver cancer (non-HCC patients).

Exclusion Criteria:

1. pregnant women;

2. Have received an organ transplant;

3. Non-HCC patients diagnosed with other tumors;

4. Patients with primary hepatocellular carcinoma combined with other tumors;

5. The investigator judges that they are not eligible for inclusion.

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Liver Cancer

Locations

Country	Name	City	State
China	Beijing Youan Hospital,Capital Medical University Beijing Institute of Hepatology	Beijing
China	Xiangya Hospital of Central South University	Changsha
China	West China School of Medicine/West China Hospital of Sichuan University	Chengdu
China	Guangzhou eighth People's Hospital ,Guangzhou Medilcal University	Guangzhou
China	The Third Affiliated Hospital of Sun Yat-sen University	Guangzhou
China	Nantong Tumor Hospital	Nantong
China	Ruijin Hospital, Shanghai Jiaotong University School	Shanghai
China	Wuxi No.5 People's Hospital	Wuxi
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou

Sponsors (11)

Lead Sponsor

Collaborator

Genetron Health

Beijing Youan Hospital,Capital Medical University Beijing Institute of Hepatology, Guangzhou eighth People's Hospital ,Guangzhou Medilcal University, Peking University First Hospital, Ruijin Hospital, Shanghai Jiaotong University School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First Affiliated Hospital of Zhengzhou University, Third Affiliated Hospital, Sun Yat-Sen University, West China School of Medicine/West China Hospital of Sichuan University, Wuxi No.5 People's Hospital, Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All plasma samples and imaging results will be used to evaluate diagnostic(sensitivity and specificity) of the kit.	Alpha-fetoprotein (AFP), liver ultrasound (US), dynamic contrast enhanced MRI and the kit examination will be performed on high-risk participants of primary liver cancer.; For subjects with typical imaging findings of hepatocellular carcinoma but an intrahepatic nodule diameter of =2 cm, an imaging study will be added to the above.; According to the clinical diagnostic criteria of primary liver cancer, the diagnostic performance of the kit, liver ultrasound examination (US) combined with alpha fetoprotein (AFP) detection will be evaluated, and the sensitivity of the kit, the kit combined with AFP, the kit combined with AFP and US, AFP combined with US screening for primary liver cancer will be compared.	2 months
Primary	Plasma samples of patients with and without HCC to evaluate test performance(accuracy) of the kit. diagnostic(sensitivity and specificity) of the kit.	Following the principle of simultaneous blinding, blood samples were collected from liver cancer patients and non-HCC patients who had been diagnosed according to the clinical diagnostic criteria for primary liver cancer. The subjects were coded, and the selected samples were tested by the kit and the comparison method high-throughput human methylation sequencing (NGS sequencing method), and the test results were compared.	2 months